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Comparison of fluticasone propionate and 
beclomethasone dipropionate on direct and 
indirect measurements of bronchial 
hyperresponsiveness in patients with stable 
asthma
G  P Bootsma, P N R  Dekhuijzen, J Festen, P G  H  M ulder, C L  A van Herwaarden
Abstract
Background -  Fluticasone propionate is 
a new inhaled corticosteroid with a 2:1 
efficacy ratio compared with beclo­
methasone dipropionate with regard to 
lung function and symptom scores, with­
out increased systemic activity. The aim  
of this study was to investigate whether 
this was also the case for bronchial hyper­
responsiveness, assessed by both a direct 
(histamine) and an indirect (ultrasonically 
nebulised distilled water (UNDW)) pro­
vocation test.
Methods -  Fluticasone propionate, 750 \igl 
day, and beclomethasone dipropionate, 
1500 fig/day, were compared in a ran­
domised, double blind, crossover study 
consisting o f two six week treatment 
periods, each preceded by a three week 
single blind placebo period. Twenty one 
non-smoking asthmatics (mean forced ex­
piratory volume in one second (FEV^ 
74*7% predicted, mean PC20histamine 
0*36 mg/ml) completed the study.
Results -  Fluticasone propionate and 
beclomethasone dipropionate improved 
FEV15 peak flow rates, asthma symptoms, 
and bronchial hyperresponsiveness to the 
same extent. Both fluticasone propionate 
and beclomethasone dipropionate caused 
an increase in PC20histamine (mean 2*29 
[95% confidence interval 1*45 to 3*13] and 
1*95 [1*07 to 2-84] doubling doses, re­
spectively) and in PD 20UNDW (1*12 [0-55 
to 1*70] and 1-28 [0*88 to 1*70] doubling 
doses, respectively). Neither treatment 
changed morning serum cortisol levels, 
but fluticasone propionate decreased the 
number of peripheral blood eosinophils 
less than beclomethasone dipropionate, 
indicating smaller systemic effects of flu­
ticasone propionate.
Conclusions -  These findings show that 
fluticasone propionate is as effective as 
twice the dose of beclomethasone dipro­
pionate on bronchial hyperresp onsive- 
ness, assessed by provocation with both 
histamine and UNDW, without increased 
systemic activity.
( Thorax 1995;50:1044-1050)
Keywords: bronchial hyperresponsiveness, fluticasone 
propionate, beclomethasone dipropionate.
Inhaled corticosteroids are currently the most 
effective anti-inflammatory drugs available for 
the treatment of asthma.1“3 Dosages above 
1000 |4.g/day may be necessary to control severe 
asthma, but these dosages are associated with 
systemic effects including a decrease in morn­
ing cortisol levels and adverse effects on para­
meters of bone turnover.3
Fluticasone propionate is a new inhaled corti­
costeroid with higher topical anti-inflammatory 
potency in humans than beclomethasone di­
propionate and budesonide.'4 Comparative 
studies indicate a 2:1 clinical potency ratio of 
fluticasone propionate compared with these 
inhaled steroids over a range of 200-1000 j-ig 
fluticasone propionate daily.5 9 In these trials 
forced expiratory volume in one second (FEVj), 
peak expiratory flow rate (PEFR), and symp­
tom scores were used to evaluate clinical
efficacy.
No comparisons have been made between 
fluticasone propionate and other inhaled ster­
oids with regard to bronchial hyperrespons­
iveness, a major characteristic of asthma. Bron­
chial hyperresponsiveness can be measured by 
pharmacological (direct) stimuli such as his­
tamine. Ultrasonically nebulised distilled water 
(UNDW), a physiological stimulus, induces 
airway narrowing indirectly and may better 
reflect the clinical severity of asthma.1011
The aim of this study was to compare the 
effects of inhaled fluticasone propionate 
(375 jjLg twice daily) and inhaled beclo­
methasone dipropionate (750 j-ig twice daily) 
on bronchial hyperresponsiveness (assessed by 
provocation with histamine and UNDW), and 
on clinical efficacy in adult patients with stable 
asthma.
Methods
DESIGN AND TREATMENT
The study was a randomised, crossover trial, 
with a three week single blind washout (pla­
cebo) period before each of the two six week 
double blind active treatment periods. A 
schematic overview is shown in fig. 1. Currently 
used inhaled corticosteroids were discontinued 
at the start of the first placebo (washout) period. 
Measurements made at the end of the two 
placebo (washout) periods were regarded as 
baseline values before the active treatment 
periods. After the first placebo (run in) period
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Figure 1 Design o f the study. FP=fluticasone propionate 750 fig daily; BD P  
beclomethasone dipropionate 1500 fig daily.
a final evaluation was made to check if the 
patient met all inclusion criteria. If so, they 
randomly received fluticasone propionate 
750 jag daily or beclomethasone dipropionate 
1500 jig daily for six weeks.
Throughout the study the patients took three 
inhalations of the study medication twice daily. 
The inhalations were taken from a metered 
dose inhaler containing either placebo, flu­
ticasone propionate 125 jig, or beclomethasone 
dipropionate 250 i^g per dose. The patients 
used a salbutamol metered dose inhaler 
(100 jig) as required as rescue medication. 
Patients were instructed on the correct usage 
of their inhaler. No other pulmonary med­
ication was allowed.
SUBJECTS
Thirty adult non-smoking patients with asthma 
according to the criteria of the American Thor­
acic Society12 were recruited from the out­
patient department. Baseline characteristics of 
these subjects are shown in table 1. All but one 
used inhaled corticosteroids before entering the 
study, with a mean (SE) daily dose of 790 (54) 
jig. At the start of the first placebo (washout 
and run in) period patients discontinued their 
inhaled steroids. Allergy was defined as raised 
specific IgE levels or positive skin tests for 
housedust mite or two of seven other common 
aeroallergens tested.13 To be included in the 
study patients needed to be symptomatic, 
defined as having ^ 4  symptom days during 
the last week3 or ^  7 symptom days during the 
last two weeks of the first placebo (run in) 
period. Days were considered as symptom days 
when patients recorded at least one asthma 
symptom on the record cards (see below) dur­
ing that day. At the end of the run in period, 
FEV, had to be ^50%  of predicted and 
patients needed to have a provocative con­
centration of histamine causing a 20% fall in 
FEV\ (PC2ohistamine) below 4 mg/ml, in­
dicating overt bronchial hyperresponsiveness.J4 
Subjects with seasonal allergy did not par­
ticipate in the study during that specific season. 
None of the patients had used systemic corti­
costeroids in the six months preceding the 
study. Patients with an upper or lower res-
piratory tract infection within six weeks before 
the start o f the study were excluded. The study 
was approved by the Nijmegen University med­
ical ethics committee. All subjects gave written 
informed consent.
BRONCHIAL HYPERRESPONSIVENESS AND LUNG 
FUNCTION
At the end of the four periods a histamine and 
a U N D W  provocation test were performed at 
the same time on two different days in order 
to avoid tachyphylaxis for the different tests.15 
Subjects did not use rescue or study medication 
for at least eight hours before each visit* and 
rested 15 minutes before the measurements 
were started.
Lung function and responses to provocation 
with histamine (PC 2ohistamine) and U N D W  
(PD2oUNDW) were assessed by FEVj, mea­
sured with a flow-volume curve recorded on a 
heated pneumotachograph (Spiro analyser ST 
250; Fukuda Sangyo Co, Tokyo, Japan). Base­
line lung function was recorded as the best of 
three reproducible values of FEVi (within 5%) 
before the provocation tests.
The histamine provocation test was carried 
out according to the method of Cockcroft et 
a l li For two minutes patients inhaled doubling 
concentrations of histamine acid phosphate by 
tidal breathing, increasing from 0 ’03 to 16 mg/ 
m l  Histamine was nebulised with a DeVilbiss 
646 nebuliser (DeVilbiss, Somerset, Penn­
sylvania, USA) with a fixed output of 0*13 ml/ 
min, P C 2ohistamine was determined in mg/ml 
by interpolating the last two points of the dose- 
response curve on a semilogarithmic scale.
The U N D W  provocation test was performed 
according to the m ethod of Groot et a l 15 
U N D W  was generated with an ultrasonic 
nebuliser (Ultraneb 99^ DeVilbiss, Somerset, 
Pennsylvania, USA) at a fixed output of 2-00 
(0* 05) ml/min. After inhalation of 20 litres of 
ambient air through the system, patients in­
haled doubling volumes of air with U N D W  (3, 
5,10, up to 160 litres), measured with a Wright 
respirometer (British Oxygen Co, London, 
UK). T he respirometer was placed between 
the aerosol hose and the mouthpiece by means 
of a two way valve. Before and after each test 
the nebuliser chamber and aerosol hose were 
weighed to determine the exact am ount of 
distilled water inhaled. T he cumulative amount 
of inhaled water (ml H 20 )  causing a 20% fall 
in FEV3 from post-air values (PD20U N D W ) 
was calculated by linear interpolation on a 
semilogarithmic curve.
DAILY RECORD CARDS
During the last three weeks of each of the four 
periods, patients recorded PEFR, use of study 
and rescue inhaler, asthma symptoms, and ad­
verse events every day. T he best of three PE FR  
measurements with a mini-Wright peak flow 
meter was recorded every morning and evening, 
before medication. T he  severity of dyspnoea 
during the day, during the night, and during 
exercise was registered on a visual analogue 
scale ranging from 0 to 100 m m .16
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LABORATORY EVALUATION
At the end of the four treatment periods a 
peripheral blood sample was taken between 
0700 and 0900 hours (individual patients al­
ways at the same dme) for measurement of 
total numbers of eosinophils and cortisol.
Total numbers of eosinophils were measured 
with a Technicon H I analyser (Technicon 
Instrument Co, Tarry town, New York, USA). 
Cortisol levels were immediately determined 
using an in-house radioimmunoassay involving 
heat inactivation of corticosteroid binding 
globulin. The lower limit of normal for 
morning serum cortisol levels 
laboratory is 0*19 junol/1.
in our
STATISTICAL ANALYSIS
Treatments were randomly allocated to five 
groups of six patients each according to the 
PACT computer programme. Each con­
secutive patient was allocated the next ran- 
domisation number after meeting the entry 
criteria at visit 1.
Four repeated measurements were made, at 
the start and at the end of each of both treat­
ment periods (measurements 1-4, fig I). The 
carryover effect of the first treatment at the 
start of the second treatment period (measure­
ment 3) is a first order carryover effect, which 
may still be partly present at the end of the 
second treatment period (measurement 4). 
This latter part is the second order carryover 
effect which may interfere with the treatment 
effect. T he first order carryover effect was 
tested by comparing the differences of meas­
urements 3 and 1 between the two randomised 
treatment groups. Theoretically the second 
order carryover effect is tested by comparing 
the sum of measurements 2 and 4 between 
the treatment order groups.17 However, in the 
present study some imbalance was present in 
several outcome variables between the two 
treatment groups at the start of the study, 
despite randomisation. In order to correct for 
this imbalance present at measurement 1, the 
second order carryover effect was tested by 
comparing the sum of two differences -  that 
is* 2 minus 1 and 4 minus 1 -  between the two 
treatment groups. Provided that there was no 
second order carryover effect, the treatment 
effect was tested next by comparing the differ­
ence of measurements 2 and 4 between the 
treatm ent order groups. The treatment effect 
“fluticasone propionate (FP) minus be­
clomethasone dipropionate (BDP)55 was es­
timated by taking half the difference between 
the two treatment order groups of the within 
group mean differences of measurements 2 and
Table 1 M ean ($D) baseline characteristics of the patients
A t  start of study 
(n= 30)
After first placebo 
(run in) period (n — 21)
Sex (M/F) 14/16 10/11
Age (years) 30-3 (7-4) 30-2 (8*1)
Allergy (positive) 25 18
FEV, (% pred) 84-8 (18-8) 74-7 (18*1)
log2PC20histamine (mg/ml) -2 -8 5  (1*98)
log2PD 20U N D W  (ml H zO) 0-92 (1-73)
PC 20histamine=provocative concentration of histamine causing a 20% fall in FEV^ 
PD 20U N D W  — provocative dose o f ultrasonically nebulised distilled water causing a 20% fall in
FEV,.
4: ( ( F P - B D P ) - ( B D P - F P ) ) /2 .17 Altern­
atively, the clinical efficacy of each treatment 
was also expressed by taking the differences 
between the measurements at the end of either 
treatment period and the associated baseline 
measurement at the start of the treatment 
period considered.
All PC20histamine and PD 20UNDW data 
were log2 transformed before analysis, hence 
changes in PC 20histamine and PD20UNDW
were expressed as doubling doses of inhaled 
histamine and UNDW. The standard deviation 
of the differences between two repeated 
measurements (SD-rm) for these provocation 
tests was calculated between the two baseline 
values.18 From the parameters recorded on the 
diary card (PEFR, symptom scores, additional 
use of broncho dilator) the mean of all values 
recorded during the last two weeks of each 
period was used for statistical analysis. PEFR 
variability was defined as the difference be­
tween morning and evening reading (highest 
minus lowest value), expressed as a percentage 
of the mean of both readings.19 The Wilcoxon 
signed rank test or the paired t test were used for 
analysis when appropriate. Correlations were 
calculated by means of the Spearman rank 
correlation coefficient, p values of <0*05 being 
considered significant. Data are reported as 
mean (SE) values unless specified otherwise.
Results
Thirty patients entered the first placebo (run 
in) period. Two patients did not meet the final 
criteria after the run in period because they
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Figure 2 Mean (SE) values o f (A) PC2qH  (provocative 
concentration of histamine causing a 20% fall in FEV¡) 
and (B) PD2oUNDW  (provocative dose of ultrasonically 
nebulised distilled water earning a 20% fall in F E V J .  □ ,  
beclomethasone dipropionate (BDP); W, fluticasone 
propionate (FP).
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experienced no asthma symptoms during that 
period. Seven patients dropped out in the run 
in period because of an exacerbation of their 
asthma after withdrawal of their inhaled corti-
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Figure 3 Morning (am) (-—)  and evening (pm) ( —)  
peak expiratory flow rates (PÉFR) during the three week 
placebo (washout) period and after 3 -6  weeks of treatment 
with (A) fluticasone propionate (FP) 750 \igiday and (B )  
beclomethasone dipropionate (BDP) 1500 fig!day.
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Figure 4 Change in individual morning serum cortisol values from baseline to six weeks 
after treatment and mean (XJ) (SE) values with fluticasone propionate (FP) 750 P-giday 
( 0 )  and beclomethasone dipropionate (BDP) 1500 fig Iday (O)* The lower limit o f 
normal (O'19 ¡xmolll) is indicated at the bottom of the figure.
costeroid. The remaining 21 patients all com­
pleted the study. O f these patients, 14 started 
with beclomethasone dipropionate and seven 
with fluticasone propionate. Since patients 
actually dropped out on the basis of pre­
randomisation criteria, this did not affect the 
validity of the study.
There were no first and second order carry­
over effects for any variable measured. The 
treatment effects of fluticasone propionate and 
beclomethasone dipropionate were therefore 
compared by analysing the difference of meas­
urements 2 and 4 between the treatm ent order 
groups (table 2). Furthermore, the clinical 
efficacy of both inhaled steroids was analysed 
by comparing the treatment effects with their 
own baseline value (table 2) (A effects). No 
significant differences were found in any vari­
able at the end of each placebo period.
BRONCHIAL HYPERRESPONSIVENESS AND LUNG  
FUNCTION
Both fluticasone propionate and beclo­
methasone dipropionate caused a significant 
decrease in bronchial hyperresponsiveness. On 
average, P C 20histamine increased by 2*29 [95% 
confidence interval (Cl) 1-45 to 3*13] and by 
1 -95 [1 ‘07 to 2*84] doubling doses, respectively 
(both p<0*001). PD20U N D W  increased by 
1*12 [0-55 to 1-70] and by 1*28 [0*88 to 1*70] 
doubling doses, respectively (p<0-001 and 
p<0*005, respectively) (fig 2), The SD-rm of 
the two baseline measurements was 0*33 doub­
ling doses for the histamine provocation test 
and 0-23 doubling doses for the U N D W  pro­
vocation test.
PC20histamine and PD20U N D W  were sig­
nificantly correlated both after placebo (p =  
0-74; p < 0*001) and after treatm ent with flu­
ticasone propionate (p =  0*54; p<0-05) and b e­
clomethasone dipropionate (p =  0*51; p<0-05). 
There were no significant differences between 
the effects of fluticasone propionate and be­
clomethasone dipropionate on bronchial 
hyperresponsiveness and FEVi (table 2). FEV-! 
increased by 0-45 (0*12) 1 after fluticasone pro­
pionate (from 74-1% to 86-9% predicted; 
p < 0-005), and by 0*34 (0*09) 1 after beclo­
methasone dipropionate (from 76*4% to 85*8% 
predicted; p<0-001).
DAILY RECORD CARDS
Compared with baseline values, PE FR  showed 
increases in morning and evening values after 
both fluticasone propionate and beclo­
methasone dipropionate (all p<0*01). The di­
urnal variation in PEFR decreased significantly 
after fluticasone propionate bu t no t after be­
clomethasone dipropionate (table 2, fig 3). T he 
treatm ent effects of fluticasone propionate and 
beclomethasone dipropionate were not sig­
nificantly different (table 2).
The use of (32 agonists decreased significantly 
compared with baseline, both with fluticasone 
propionate and beclomethasone dipropionate, 
the treatm ent effect not being different with 
either steroid (table 2). Dyspnoea scores, re­
corded on a visual analogue scale, decreased
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Table 2 Clinical efficacy and mutual comparison o f fluticasone propionate (FP) and beclomethasone dipropionate
(BDP)
Parameter Baseline 
(mean (SE))
After 6 weeks 
treatmentt  
(mean (SE))
Difference in treatment effect$
FP -  BD P
Mean (SE) 95% CÎ
PC2(>histamine (mg/ml)
FP 0-41 (0*17) 2-42 CO' 17)***
0*55 (0*3) D D - 0*10 to 1*21
BDP 0-49 (0-24) 1-63 (0-61)***
PD20UNDW  (ml H 20 )
FP 3-77 (1-00) 8*62 (1‘93)***
0*03 (0*3) D D — 0*63 to 0*65
BDP 3*29 (0-91) 7-63 (1*78)**
FEV,(1)
FP 2*83 (0-18) 3*28 (0*13)**
0*06 (0*07) — 0*08 to 0*21
BDP 2*90 (0-15) 3*24 (0-14)**
PEFR morning (1/min)
FP 438*4 (21-2) 489*9 (17-3)***
5*57 (5*5) 6*31 to 17*5
BDP 433*6 (208) 479*9 (17-7)***
PEFR evening (1/min)
FP 448*1 (17*2) 487-9 (15-8)***
2*69 (6*5) — 10*9 to 16*3
BDP 445-3 (16*3) 474*5 (15-0)**
Diurnal variation (%)§
FP 6*89 (0-90) 3*97 (0*50)**
-0*59 (0*64) —1*93 to 0*76
BDP 8*70 (1*92) 5-11 (0*59)
(i2 agonist use (puffs/day)
FP 2-23 (0*35) 1*03 (0-29)***
-0*25 (0*22) -0*72 to 0-21
BDP 2*36 (0-43) 1*40 (0-34)**
f A  treatment effects are calculated as treatment values versus corresponding baseline values. NS =  not significanti * * p < 0 0 1 ;
***p<0‘00U
$ Treatment effects o f FP and BDP are directly compared by analysing the difference of their treatment effects between treatment 
order groups ((FP — BDP) -  (BDP — FP))/2,
§ Difference between morning and evening reading expressed as percenatage of the mean of both readings.
during daytime from 18*1 (2‘7) to 7-3 (2*1) 
mm after fluticasone propionate and from 14*8 
(3*0) to 6*4 (1*9) mm after beclomethasone 
dipropionate (both p<0*001). Night time dys­
pnoea scores decreased from 17*1 (2*9) to 5*6 
(2*0) mm after fluticasone propionate and from 
14-9 (3*6) to 5*9 (2*2) mm after beclo­
methasone dipropionate (both p<0*001). 
There were no significant treatment effects 
between fluticasone propionate and beclo­
methasone dipropionate.
No serious adverse events were reported dur­
ing the study. During treatment with both flu­
ticasone propionate and with beclomethasone 
dipropionate three subjects reported a sore 
throat not related to a common cold. Other 
adverse events* unlikely to be related to the use 
of the study drugs* included common cold 
(seven times with fluticasone propionate* four 
times with beclomethasone dipropionate* and 
six times with placebo)* nausea and stomach 
ache (twice with beclomethasone dipro­
pionate)* headache (once with fluticasone 
propionate* three times with beclomethasone 
dipropionate and five times with placebo)* diar­
rhoea (once both with fluticasone propionate 
and beclomethasone dipropionate)* and gen­
eralised itching (three times with placebo).
LABORATORY EVALUATION
The total number of eosinophils in the peri­
pheral blood decreased from 0*45 to 0*22 
x 109/1 (p<0*001) after beclomethasone di­
propionate* and from 0-41 to 0*30 x 109/1 
(p<0*001) after fluticasone propionate. This 
treatm ent effect was significantly different* with 
a mean difference between fluticasone pro­
pionate and beclomethasone dipropionate of 
0*076 x 1071 (95% Cl 0*024 to 0*13).
Neither fluticasone propionate nor b e ­
clomethasone dipropionate affected m orning 
cortisol levels significantly* as shown in fig 4. 
The seven patients with high values of m orning 
cortisol (>0*70 |imol/l) were all women* six of 
whom were taking oral contraceptive drugs. 
Oestrogens in oral contraceptive drugs are 
known to increase the production of corti­
costeroid binding globulin* which probably ac­
counts for the high values of cortisol in these 
patients.20 The only patient with a large de­
crease (0*45 jimol/1) in morning cortisol levels 
after treatment with beclomethasone di­
propionate also showed a substantial decrease 
(0*25 j.imol/1) after treatment with fluticasone 
propionate. In no patient did the cortisol level 
fall below the lower limit of normal after treat­
ment. Mean cortisol values did not change 
significantly (from baseline 0*64 to 0*61 jimol/ 
1 after fluticasone propionate* and from baseline 
0-60 to 0*59 jimol/1 after beclomethasone d i­
propionate). There was no difference in trea t­
ment effect between fluticasone propionate an d  
beclomethasone dipropionate.
Discussion
This study in patients with stable asthma shows 
that* after six weeks of treatment* fluticasone 
propionate 750 jug daily is as effective as b e ­
clomethasone dipropionate 1500 \xg daily. N o  
significant differences in beneficial effects were 
found with regard to bronchial hyper­
responsiveness* FEVi* PEFR* and asthm a 
symptoms. Both fluticasone propionate an d  
beclomethasone dipropionate caused a sig­
nificant decrease in bronchial hyper­
responsiveness* assessed by both the histam ine 
and the UNDW  provocation test. N either
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steroid significantly changed morning cordsol 
levels.
This is the first study to test the hypothesis 
that fluticasone propionate may provide an 
equal effect on bronchial hyperresponsiveness, 
a major characteristic of asthma, at half the 
microgram dose of beclomethasone di­
propionate. Until now all comparative studies 
in mild, moderate, and severe asthmatics have 
shown a 2:1 ratio in clinical effects. This was 
shown over a wide dose range, from 200 to 
1000 (ig fluticasone propionate (400-2000 \xg 
beclomethasone dipropionate,5"7 and 400 jug 
budesonide8). Furthermore, in an open study 
400 \ig fluticasone propionate was more effect­
ive than 800 |ag budesonide,9 and both 1000 
and 2000 [ig fluticasone propionate were sig­
nificantly more effective than 1600 \ig bu­
desonide.21 Fabbri et aP2 compared fluticasone 
propionate and beclomethasone dipropionate 
in an equal dose (1500 \xg daily) in patients 
with moderate to severe asthma. Fluticasone 
propionate caused a significantly greater in­
crease in asthma control than beclomethasone 
dipropionate. The present study confirms a 
similar ratio with regard to lung function, 
PEFR, symptom scores, and use of (32 agonists 
as that shown in previous comparative trials.46~9 
On all parameters fluticasone propionate was 
as effective as twice the dose of beclomethasone 
dipropionate (table 2).
The extent to which fluticasone propionate 
and beclomethasone dipropionate reduced 
bronchial hyperresponsiveness is in line with 
that in previous studies. In mild asthmatics 
fluticasone propionate 1000 \xg daily for two 
weeks improved PC20histamine by 1 *3 doubling 
doses.23 The average increase in PC 20histamine 
or methacholine after chronic treatment with 
beclomethasone dipropionate or budesonide, 
as recently reviewed by Barnes et al, 3  is also of 
the order of one or two doubling doses. The 
extent of the response depends on dose, dur­
ation of treatment, and degree of steroid res­
ponsiveness. Treatment with a similar dose of 
budesonide (1600 jag daily) during six weeks 
improved PD20histamine by 2*4 doubling 
doses24 compared with 2*3 doubling doses for 
fluticasone propionate and 2*0 doubling doses 
for beclomethasone dipropionate in this study. 
The extent of the increase in PD20UNDW  (1*1 
and 1 *3 doubling doses) is slightly less than in 
the study of Groot et aP5 (1*8 doubling doses 
after four weeks of beclomethasone di­
propionate 800 jag daily). This may be ex­
plained by the fact that at baseline our patients 
were less responsive to UNDW, the 
PD20UNDW  being 3*3 and 3-8 ml H 20 , com­
pared with 1-3 ml H 20  in the study by Groot 
et a l25
To assess efficacy of treatment an indirect 
challenge, as with UNDW, may be preferable 
because it mimicks naturally occurring bron- 
choconstrictor stimuli and because it reflects 
the severity of asthma better.1011 Inhaled his­
tamine acts mainly directly on the airway 
smooth muscle.10 In contrast, UNDW  induces 
bronchoconstriction by cell-mediated events.11 
Challenge with UNDW  may increase bronchial 
hyperresponsiveness and induce a late asth­
matic response, just as exposure to allergens.26 
It has been suggested that inhaled cortico­
steroids may have a greater effect on indirect 
than on direct challenges, because they not 
only affect smooth muscle responsiveness but 
also reduce the airway mast ceil function.27 
This concept could not be confirmed in the 
present study because both fluticasone pro­
pionate and beclomethasone dipropionate 
caused a strong decrease in bronchial hyper­
responsiveness in both tests. Com pared with 
the SD-rm of the challenges, both steroids 
improved the P C 30histamine about sixfoldj and 
the P D 20U N D W  about fivefold, indicating 
equal effects on both parameters. Similarly, the 
study of Groot et aP5 showed no advantage of 
U N D W  over histamine. Nevertheless, the low 
correlation coefficient between P C 20histamine 
and P D 2oUNDW after treatm ent indicates that 
both challenges test different aspects of bron­
chial hyperresponsiveness.
A potential drawback of our study was the 
crossover design, because it may take several 
weeks before bronchial hyperresponsiveness re­
turns to baseline values after discontinuation 
of inhaled steroids.28 However, after the second 
washout period (measurement 3) all para­
meters, including bronchial hyperrespons­
iveness, returned to pretreatm ent levels 
(measurement 1). Therefore, carryover effects 
are not likely to have affected the outcome in 
the present study both from a statistical point 
of view and in terms of clinical relevance.
Fluticasone propionate may offer some ad­
vantages over previous inhaled steroids due to 
its negligible oral bioavailability.29 However, the 
systemic effects of inhaled corticosteroids are 
mainly due to their resorption from the airways. 
The use of a spacer device may increase lung 
deposition and thus systemic absorption.3 
There is no evidence for local metabolism of 
fluticasone propionate in the lung. T he  sys­
temic concentration will be reduced by con­
tinuous recirculation and inactivation in the 
liver; the hepatic extraction ratio of fluticasone 
propionate is almost 100%.4 This may offer 
some advantages over beclomethasone di­
propionate. In the lung beclomethasone di­
propionate is hydrolysed to its m uch more 
active metabolite beclomethasone-17-mono­
propionate (17-BMP)j and the majority of 17- 
BMP will reach the circulation. We did not use 
a spacer device in the present study. It is pos­
sible tliat the use of a spacer would have in­
creased the systemic effects. However, the use 
of a spacer is no t likely to have changed the 
difference between the two drugs.
With regard to the systemic effects o f inhaled 
corticosteroids, two studies have shown sig­
nificant differences in the effect on the hypo­
thalamic-pituitary-adrenal (HPA) axis between 
fluticasone propionate and beclomethasone di­
propionate in adult asthmatics. In the study by 
Leblanc et al6 200 jig fluticasone propionate 
daily increased serum cortisol levels com pared 
with a (non-significant) decrease after 400 jxg 
beclomethasone dipropionate. In addition, 
tetracosactrin-stimulated cortisol levels were 
significantly higher after fluticasone p ro­
pionate. In the study of Barnes and co workers7
1050 Bootsma, Dekhuijzen3 Festen, Mulder, van Herwaarden
serum cortisol levels rose from 0*29 to 
0*31jimol/l after fluticasone propionate 
1000 ¡ig daily, and decreased from 0-26 to 
0 ’22 jamol/1 after beclomethasone dipropionate 
2000 |ig daily, tlie treatment effects being sig­
nificantly different. In our study serum cortisol 
levels did not change significantly with rel­
atively high doses of inhaled steroids, which 
corresponds widi the findings by Ayres et a l 21 
However, most studies (including ours) only 
measured morning serum cortisol levels^ a 
simple but insensitive method to detect changes 
in the adrenal function. This was demonstrated 
in the study by Nicolaizik et al30 who showed 
that morning serum cortisol levels did not 
change during treatment with budesonide and 
beclomethasone, but that 24 hour urinary se­
cretion of free cortisol was decreased. In ad­
dition, our patients inhaled steroids without a 
spacer, and the duration of active treatment 
with each of the drugs studied was only six 
weeks. These factors may partly explain our 
inability to detect any change in adrenal func­
tion. On the other hand, we did detect a sig­
nificant difference in absolute eosinophil 
counts in the peripheral blood5 also a sensitive 
indicator of systemic activity.31 Absolute num ­
bers of eosinophils decreased less with flu­
ticasone propionate than with beclomethasone 
dipropionate, the treatment effect being sig­
nificantly different (p<0’01). In this respect 
fluticasone propionate showed less systemic 
activity than beclomethasone dipropionate.
In conclusion^ fluticasone propionate 750 p,g 
daily is as effective as beclomethasone di­
propionate 1500 jag daily with regard to bron­
chial hyperresponsiveness and clinical efficacy, 
while the systemic activity is not increased.
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